AAV Vector Suspension

Our best-in-class AAV Vector Suspension Platform enables cell and gene therapies to be developed, manufactured, and released faster and with greater predictability

WuXi Advanced Therapies’ integrated single-source, in-house platform – with in-stock raw materials with established batch records, enhanced manufacturing scalability and flexibility, and complete testing capabilities – is a time-sensitive solution that produces high-quality AAV vectors to meet not only your needs but also the requirements of international regulatory agencies.


Platform Features

  • Industry-leading experience with robust scalability and consistent predictability.
  • Enhanced manufacturing capacity and scheduling flexibility
    to meet customer timelines.
  • End-to-end integrated solutions with dedicated process and analytical development teams to support feasibility studies, verification runs and tox material production.
  • State-of-the-art GMP manufacturing facility with single-use bioreactors ranging up to 1000 L SUB — compliant with US, EU, China and other GMP regulations.
  • Security of supply with raw materials and consumables in stock – ready for use – with established batch records.
  • Full in-process and release testing, plus complete quality control and characterization services with regulatory support.
  • Characterized MCB and WCB ready for client production.
  • Consistent product quality and productivity when process is scaled up, and downstream process that typically results in 20-40% overall yield in viral particle.

Single-Use Bioreactor Scalability

Additional Platforms

Lentiviral Vector Platform

Closed-Process Car-T Platform

Plasmid (GMP-like and GMP) Production